The impact of aromatic ring count on compound developability - are too many aromatic rings a liability in drug design? • Review article Drug Discovery Today, Volume 14, Issue 21-22, November 2009, Pages 1011-1020 | Ritchie, T.J.; Macdonald, S.J.F ..read more

Machine Learning to Design Antimicrobial Combinations Promises and Pitfalls We discuss strategies for applying machine learning methods to identify synergistic drug combinations from millions of candidates using information on the compound, pathogen and disease environment ..read more

Drug discovery in the next decade:innovation needed ASAP Drug discovery in the next decade:innovation needed ASAP The pharmaceutical sector, a cornerstone of the healthcare industry, is undergoing dramaticchange, primarily caused by reduced output of new medicines from research and development(R&D) laboratories, drug pricing pressures, stricter regulatory environments and the overallcurrent economic downturn. This makes demands of all pharmaceutical companies to find better ways to increase their output of new drugs, through innovation, to both treat patients and meet their shareholders’ e ..read more

Dr Brent Vose outlines AstraZeneca's oncology pipeline. Download the Dr. Brent Vose podcast as an mp3 file ..read more

Co-crystallization in drug development ~ Exploring the benefits of co-crystals ~ Over the last decade, co-crystallization has become an attractive alternative to improve the physiochemical properties of drugs without affecting their pharmacology. As a result of the pharmaceutical benefits co-crystals exhibit, industrial interest is on the rise. Here Dr. Thomas Kendall, application specialist at crystallization and solid-state specialist Technobis Crystallization Systems, gives a perspective on the benefits of co-crystals and explains how they can be screened ..read more